Janus kinase 2 inhibitors in myeloproliferative disorders

Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283

(2011) Jayne Curry et al.   CELL CYCLE

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells

(2010) R. Tanaka et al.   BLOOD

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

(2010) P. Koppikar et al.   BLOOD

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice

(2010) C. Marty et al.   BLOOD

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

(2010) N. H. Thoennissen et al.   BLOOD

Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells

(2010) Ann Mullally et al.   CANCER CELL

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria

(2010) Martha Wadleigh et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias

(2010) F. Fei et al.   MOLECULAR CANCER THERAPEUTICS

From Palliation to Targeted Therapy in Myelofibrosis

(2010) Alessandro M. Vannucchi   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm

(2009) P. A. Beer et al.   BLOOD

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

(2009) Ayalew Tefferi et al.   Nature Reviews Clinical Oncology

Polyphosphate enhances fibrin clot structure

(2008) S. A. Smith et al.   BLOOD

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

(2008) F. Patriarca et al.   HAEMATOLOGICA

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY

Genetic complexity of myeloproliferative neoplasms

(2008) R Kralovics   LEUKEMIA

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

(2008) T L Lasho et al.   LEUKEMIA

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

(2008) O Kilpivaara et al.   LEUKEMIA

JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies

(2008) William Vainchenker et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Mining for JAK–STAT mutations in cancer

(2008) Stefan N. Constantinescu et al.   TRENDS IN BIOCHEMICAL SCIENCES